Neurocrine Biosciences
NBIX
NBIX
549 hedge funds and large institutions have $12.5B invested in Neurocrine Biosciences in 2023 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 205 increasing their positions, 197 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
549
Holders Change
+41
Holders Change %
+8.07%
% of All Funds
8.05%
Holding in Top 10
12
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+9.09%
% of All Funds
0.18%
New
92
Increased
205
Reduced
197
Closed
43
Calls
$64.4M
Puts
$54.6M
Net Calls
+$9.73M
Net Calls Change
-$6.76M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$360M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$138M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$67.3M |
| 4 |
Renaissance Technologies
New York
|
+$52.5M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$48.1M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$156M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$82.2M |
| 3 |
Millennium Management
New York
|
-$76.3M |
| 4 |
Bank of New York Mellon
New York
|
-$73.8M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$49.5M |
